Focal Point |

Genome editing and gene therapy in Japan

Japan’s gene therapy and genome editing boom

The timing is right, as intensified commercial interest collides with maturing research in these cutting-edge fields.

Focal Point feature

Partner contents

Pentatricopeptide repeat (PPR) technology can precisely edit Both RNA and DNA. Free of CRISPR’s intellectual property mire, this system could revolutionize gene therapy.

Advertisement Feature |

Mitsubishi Tanabe Pharma Corporation has invested in cutting-edge gene therapy projects for critical limb ischaemia and haemophilia B, as well as a bold new research facility.

Advertisement Feature |

A long history of research on safe and efficient delivery has put Jichi Medical University at the centre of a number of important gene-therapy clinical trials for neurological disorders.

Advertisement Feature |